TISIDB

Summary
Symbol	FOXF1
Name	forkhead box F1
Aliases	FREAC1; FKHL5; ACDMPV; FREAC-1; Forkhead, drosophila, homolog-like 5; forkhead-related activator 1; forkhead ......
Chromosomal Location	16q24
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Nucleus
Domain	PF00250 Forkhead domain
Function	Probable transcription activator for a number of lung-specific genes.

> Gene Ontology [ TOP ]
Biological Process	GO:0001570 vasculogenesis GO:0001655 urogenital system development GO:0001701 in utero embryonic development GO:0001704 formation of primary germ layer GO:0001707 mesoderm formation GO:0001738 morphogenesis of a polarized epithelium GO:0001756 somitogenesis GO:0001763 morphogenesis of a branching structure GO:0002053 positive regulation of mesenchymal cell proliferation GO:0002263 cell activation involved in immune response GO:0002274 myeloid leukocyte activation GO:0002275 myeloid cell activation involved in immune response GO:0002279 mast cell activation involved in immune response GO:0002366 leukocyte activation involved in immune response GO:0002443 leukocyte mediated immunity GO:0002444 myeloid leukocyte mediated immunity GO:0002448 mast cell mediated immunity GO:0002683 negative regulation of immune system process GO:0002694 regulation of leukocyte activation GO:0002695 negative regulation of leukocyte activation GO:0002697 regulation of immune effector process GO:0002698 negative regulation of immune effector process GO:0002699 positive regulation of immune effector process GO:0002703 regulation of leukocyte mediated immunity GO:0002704 negative regulation of leukocyte mediated immunity GO:0002886 regulation of myeloid leukocyte mediated immunity GO:0002887 negative regulation of myeloid leukocyte mediated immunity GO:0003002 regionalization GO:0003007 heart morphogenesis GO:0003197 endocardial cushion development GO:0003205 cardiac chamber development GO:0003206 cardiac chamber morphogenesis GO:0003208 cardiac ventricle morphogenesis GO:0003214 cardiac left ventricle morphogenesis GO:0003231 cardiac ventricle development GO:0006887 exocytosis GO:0007163 establishment or maintenance of cell polarity GO:0007224 smoothened signaling pathway GO:0007368 determination of left/right symmetry GO:0007369 gastrulation GO:0007389 pattern specification process GO:0007424 open tracheal system development GO:0007439 ectodermal digestive tract development GO:0007440 foregut morphogenesis GO:0007494 midgut development GO:0007498 mesoderm development GO:0007507 heart development GO:0009581 detection of external stimulus GO:0009799 specification of symmetry GO:0009855 determination of bilateral symmetry GO:0009952 anterior/posterior pattern specification GO:0010463 mesenchymal cell proliferation GO:0010464 regulation of mesenchymal cell proliferation GO:0010810 regulation of cell-substrate adhesion GO:0010811 positive regulation of cell-substrate adhesion GO:0014822 detection of wounding GO:0017157 regulation of exocytosis GO:0030010 establishment of cell polarity GO:0030198 extracellular matrix organization GO:0030323 respiratory tube development GO:0030324 lung development GO:0030335 positive regulation of cell migration GO:0030859 polarized epithelial cell differentiation GO:0030879 mammary gland development GO:0031016 pancreas development GO:0031348 negative regulation of defense response GO:0031589 cell-substrate adhesion GO:0032102 negative regulation of response to external stimulus GO:0032386 regulation of intracellular transport GO:0032387 negative regulation of intracellular transport GO:0032418 lysosome localization GO:0033003 regulation of mast cell activation GO:0033004 negative regulation of mast cell activation GO:0033006 regulation of mast cell activation involved in immune response GO:0033007 negative regulation of mast cell activation involved in immune response GO:0035088 establishment or maintenance of apical/basal cell polarity GO:0035089 establishment of apical/basal cell polarity GO:0035239 tube morphogenesis GO:0035282 segmentation GO:0040017 positive regulation of locomotion GO:0042692 muscle cell differentiation GO:0043062 extracellular structure organization GO:0043299 leukocyte degranulation GO:0043300 regulation of leukocyte degranulation GO:0043301 negative regulation of leukocyte degranulation GO:0043303 mast cell degranulation GO:0043304 regulation of mast cell degranulation GO:0043305 negative regulation of mast cell degranulation GO:0045055 regulated exocytosis GO:0045197 establishment or maintenance of epithelial cell apical/basal polarity GO:0045198 establishment of epithelial cell apical/basal polarity GO:0045576 mast cell activation GO:0045785 positive regulation of cell adhesion GO:0045920 negative regulation of exocytosis GO:0048286 lung alveolus development GO:0048332 mesoderm morphogenesis GO:0048333 mesodermal cell differentiation GO:0048368 lateral mesoderm development GO:0048369 lateral mesoderm morphogenesis GO:0048370 lateral mesoderm formation GO:0048371 lateral mesodermal cell differentiation GO:0048514 blood vessel morphogenesis GO:0048546 digestive tract morphogenesis GO:0048557 embryonic digestive tract morphogenesis GO:0048562 embryonic organ morphogenesis GO:0048565 digestive tract development GO:0048566 embryonic digestive tract development GO:0048567 ectodermal digestive tract morphogenesis GO:0048568 embryonic organ development GO:0048611 embryonic ectodermal digestive tract development GO:0048613 embryonic ectodermal digestive tract morphogenesis GO:0048617 embryonic foregut morphogenesis GO:0048732 gland development GO:0048754 branching morphogenesis of an epithelial tube GO:0048844 artery morphogenesis GO:0050727 regulation of inflammatory response GO:0050728 negative regulation of inflammatory response GO:0050777 negative regulation of immune response GO:0050865 regulation of cell activation GO:0050866 negative regulation of cell activation GO:0051048 negative regulation of secretion GO:0051051 negative regulation of transport GO:0051145 smooth muscle cell differentiation GO:0051147 regulation of muscle cell differentiation GO:0051150 regulation of smooth muscle cell differentiation GO:0051272 positive regulation of cellular component movement GO:0051640 organelle localization GO:0051656 establishment of organelle localization GO:0055123 digestive system development GO:0060425 lung morphogenesis GO:0060426 lung vasculature development GO:0060438 trachea development GO:0060441 epithelial tube branching involved in lung morphogenesis GO:0060446 branching involved in open tracheal system development GO:0060458 right lung development GO:0060461 right lung morphogenesis GO:0060462 lung lobe development GO:0060463 lung lobe morphogenesis GO:0060485 mesenchyme development GO:0060541 respiratory system development GO:0060562 epithelial tube morphogenesis GO:0060627 regulation of vesicle-mediated transport GO:0060644 mammary gland epithelial cell differentiation GO:0060749 mammary gland alveolus development GO:0060840 artery development GO:0060841 venous blood vessel development GO:0061030 epithelial cell differentiation involved in mammary gland alveolus development GO:0061053 somite development GO:0061138 morphogenesis of a branching epithelium GO:0061162 establishment of monopolar cell polarity GO:0061180 mammary gland epithelium development GO:0061245 establishment or maintenance of bipolar cell polarity GO:0061339 establishment or maintenance of monopolar cell polarity GO:0061377 mammary gland lobule development GO:0071407 cellular response to organic cyclic compound GO:0072001 renal system development GO:0072132 mesenchyme morphogenesis GO:0072189 ureter development GO:0090130 tissue migration GO:0090131 mesenchyme migration GO:0090162 establishment of epithelial cell polarity GO:0097070 ductus arteriosus closure GO:1903305 regulation of regulated secretory pathway GO:1903306 negative regulation of regulated secretory pathway GO:1903531 negative regulation of secretion by cell GO:2000147 positive regulation of cell motility
Molecular Function	GO:0001228 transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding GO:0003705 transcription factor activity, RNA polymerase II distal enhancer sequence-specific binding
Cellular Component	GO:0005667 transcription factor complex

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	-

Summary
Symbol	FOXF1
Name	forkhead box F1
Aliases	FREAC1; FKHL5; ACDMPV; FREAC-1; Forkhead, drosophila, homolog-like 5; forkhead-related activator 1; forkhead ......
Chromosomal Location	16q24
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between FOXF1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	FOXF1
Name	forkhead box F1
Aliases	FREAC1; FKHL5; ACDMPV; FREAC-1; Forkhead, drosophila, homolog-like 5; forkhead-related activator 1; forkhead ......
Chromosomal Location	16q24
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of FOXF1 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	FOXF1
Name	forkhead box F1
Aliases	FREAC1; FKHL5; ACDMPV; FREAC-1; Forkhead, drosophila, homolog-like 5; forkhead-related activator 1; forkhead ......
Chromosomal Location	16q24
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of FOXF1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.859	0.0464
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-1.006	0.148
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.767	0.211
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.141	0.873
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.45	0.824
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.882	0.711
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.858	0.226
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.472	0.657
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	1.108	0.299
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.196	0.642
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.603	0.293
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.475	0.0354

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of FOXF1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	7.1	7.1	0.452
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	10	10	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	3.7	0.27
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	3.7	0.314
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	4.8	4.8	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	7.7	7.7	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	2.6	2.6	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	4.5	4.5	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	1

Summary
Symbol	FOXF1
Name	forkhead box F1
Aliases	FREAC1; FKHL5; ACDMPV; FREAC-1; Forkhead, drosophila, homolog-like 5; forkhead-related activator 1; forkhead ......
Chromosomal Location	16q24
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of FOXF1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	FOXF1
Name	forkhead box F1
Aliases	FREAC1; FKHL5; ACDMPV; FREAC-1; Forkhead, drosophila, homolog-like 5; forkhead-related activator 1; forkhead ......
Chromosomal Location	16q24
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of FOXF1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by FOXF1. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	FOXF1
Name	forkhead box F1
Aliases	FREAC1; FKHL5; ACDMPV; FREAC-1; Forkhead, drosophila, homolog-like 5; forkhead-related activator 1; forkhead ......
Chromosomal Location	16q24
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of FOXF1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	FOXF1
Name	forkhead box F1
Aliases	FREAC1; FKHL5; ACDMPV; FREAC-1; Forkhead, drosophila, homolog-like 5; forkhead-related activator 1; forkhead ......
Chromosomal Location	16q24
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of FOXF1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	FOXF1
Name	forkhead box F1
Aliases	FREAC1; FKHL5; ACDMPV; FREAC-1; Forkhead, drosophila, homolog-like 5; forkhead-related activator 1; forkhead ......
Chromosomal Location	16q24
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between FOXF1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	FOXF1
Name	forkhead box F1
Aliases	FREAC1; FKHL5; ACDMPV; FREAC-1; Forkhead, drosophila, homolog-like 5; forkhead-related activator 1; forkhead ......
Chromosomal Location	16q24
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting FOXF1 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse FOXF1